The historical rank and industry rank for Swedish Orphan Biovitrum AB's EV-to-FCF or its related term are showing as below:
FRA:B6E'
s EV-to-FCF Range Over the Past 10 Years
Min: -328.13 Med: 42.37 Max: 821.59
Current: -228.45
During the past 13 years, the highest EV-to-FCF of Swedish Orphan Biovitrum AB was 821.59. The lowest was -328.13. And the median was 42.37.
FRA:B6E's EV-to-FCF is ranked worse than 100% of 509
companies
in the Drug Manufacturers industry
Industry Median: 21.93
vs FRA:B6E: -228.45
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Swedish Orphan Biovitrum AB's EV-to-FCF
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's EV-to-FCF falls into.
Swedish Orphan Biovitrum AB's current Enterprise Value is €9,509 Mil.
Swedish Orphan Biovitrum AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €204 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (FRA:B6E) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Swedish Orphan Biovitrum AB's PE Ratio for today is calculated as:
Swedish Orphan Biovitrum AB's share price for today is €22.88.
Swedish Orphan Biovitrum AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.560.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Swedish Orphan Biovitrum AB EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Swedish Orphan Biovitrum AB (FRA:B6E) Business Description
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:B6E has been successfully added to your 